RZLT logo

RZLTRezolute Inc

$3.96
$0.09
(2.31%)
Today
Closed $3.81
$0.1509
(3.96%)
After Hours
Updated: 05:59 PM EDT
Reported EarningsMay 12
Mkt Cap$375.54M
Vol1.23M
News
all
press releases
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
Zacks
News Placeholder
More News
News Placeholder
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
Rezolute says 6 of 8 patients met the primary endpoint in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.read more...
Benzinga
News Placeholder
Rezolute (RZLT) to Release Quarterly Earnings on Tuesday
Rezolute (NASDAQ:RZLT) will be releasing its Q3 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...
MarketBeat
News Placeholder
Rezolute, Inc. (NASDAQ:RZLT) Short Interest Down 21.2% in March
Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 13,353,457 shares, a decline of 21.2...
MarketBeat
News Placeholder
What is HC Wainwright's Estimate for Rezolute Q1 Earnings?
Rezolute, Inc. (NASDAQ:RZLT - Free Report) - HC Wainwright cut their Q1 2027 EPS estimates for Rezolute in a research report issued on Monday, March 30th. HC Wainwright analyst D. Tsao now...
MarketBeat
News Placeholder
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.
Zacks
News Placeholder
Rezolute (NASDAQ:RZLT) Stock Rating Upgraded by Wedbush
Wedbush upgraded Rezolute from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $2.00 to $5.00 in a report on Wednesday...
MarketBeat
News Placeholder
FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question
Rezolute shares rise after FDA feedback on sunRIZE trial; mixed efficacy, data review ahead for rare genetic disorder drug.read more...
Benzinga
News Placeholder
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Hold" from Analysts
Shares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have earned a consensus rating of "Hold" from the eleven brokerages that are presently covering the firm, MarketBeat.com reports. One equities...
MarketBeat
News Placeholder
22NW LP Invests $7.71 Million in Rezolute, Inc. $RZLT
22NW LP purchased a new position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.